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Dalfra` MG, Pacini G, Parretti E, Ragazzi E, Mello G, Lapolla
A. Elevated insulin sensitivity and -cell function during pregnancy in
mothers of growth-restricted newborns. Am J Physiol Endocrinol
Metab 301: E25–E30, 2011. First published April 5, 2011;
doi:10.1152/ajpendo.00024.2011.—The “Barker hypothesis” suggests
that low birth weight might predict future risk of developing obesity,
cardiovascular disease, and type 2 diabetes. Identification of the
causes of fetal growth restriction (FGR) is critical for preventive and
management strategies. Some studies indicate that maternal carbohy-
drate metabolism might be involved in FGR development. We aimed
to evaluate, in a large number of normotensive pregnant women with
normal glucose tolerance, the effect of insulin sensitivity and -cell
function on unexplained fetal growth. A total of 1,814 Caucasian
pregnant women with normal prepregnancy body mass index were
tested with a 75-g, 2-h glucose load (24–28 gestation wk). Insulin
sensitivity was evaluated with fasting (QUICKI) and dynamic index
(OGIS) and -cell function with a modified insulinogenic index as
AUCinsulin/AUCglucose and disposition index. FGR was a birth
weight below the 5th percentile for gestational age. FGR developed in
99 (5.5%) pregnant women that showed significantly higher QUICKI,
OGIS, insulinogenic, and disposition index with respect to women
with normal-weight babies (P  0.0001). By using multiple regres-
sion analysis in the FRG group, QUICKI and OGIS appeared as
significant independent variables (P  0.0001 and P  0.0366,
respectively). We conclude that elevated insulin sensitivity seems to
be one of the factors involved in determining unexplained fetal growth
retardation; its assessment, even only in the fasting state, could be
useful to guide any possible monitoring and therapeutic strategies to
reduce fetal complications.
oral glucose tolerance test; surrogate indices; metabolism
FETAL GROWTH RESTRICTION (FGR) is one of the leading causes of
perinatal morbidity and mortality (3). In addition, the “Barker
hypothesis” suggests that low birth weight might predict future
risk of developing obesity, cardiovascular disease, and type 2
diabetes in both the newborn child and the adult as a result of
stimulus or insult at a critical period of early development (15).
Therefore, identification of the causes of FGR is critical for
preventive and management strategies; FGR cannot always be
attributed to well-known factors such as aneuploidy, placental
insufficiency, and infection.
There is general consensus that birth weight is related
directly to insulin resistance in normal and gestational diabetic
pregnancies, indicating that maternal carbohydrate metabolism
plays an important role in fetal growth (9). In addition, it has
been observed that, post-glucose load, plasma insulin and
glucose levels are lower in women with FGR fetuses than in
women with a normal growing fetus (22, 25, 37, 39).
Caruso et al. (11) discovered that women with unexplained
FGR (not attributable to genetic or diverse related factors) had
higher insulin sensitivity, assessed by the euglycemic glucose
clamp, than a control group with infants appropriate for ges-
tational age. Therefore, a likely hypothesis is that undergrowth
may be caused by elevated maternal insulin sensitivity, leading
to reduced nutrient supply to the fetus (11). Thus, maternal
carbohydrate metabolism might be one of the factors involved
in the pathogenesis of FGR.
The euglycemic glucose clamp, the “gold standard” for
assessing insulin sensitivity, has been used in pregnancy, but
the test is complex, so most of the studies have been performed
on a small number of patients (4, 8, 10). Studies on insulin
secretion, which usually simply evaluated the area under the
concentration curve (8, 10) and only rarely used the hypergly-
cemic glucose clamp (18), have involved a small number of
subjects who, in most cases, were obese (10, 18). Evaluation of
insulin sensitivity and secretion in large numbers of subjects or
in particular conditions such as in pregnancy can be made only
with simple tests. The oral glucose tolerance test (OGTT) is
definitely “easier” to perform than the glucose clamp, can be
applied in large populations, and provides indices that have
already been applied with success for studies in pregnancy,
albeit in a limited number of subjects (21, 23).
The aim of our study was to evaluate, in a large number of
normotensive pregnant women with normal glucose tolerance,
possible relationships between metabolic parameters such as
maternal insulin sensitivity and -cell function and unex-
plained fetal growth restriction. Moreover, we evaluated the
predictive capacity of those parameters toward the insurgence
of FGR.
STUDY DESIGN AND METHODS
Among the population of pregnant women tested for gestational
diabetes mellitus (GDM) using a 75-g, 2-h glucose load during the
period between 24 and 28 wk of gestation at the Perinatal Medicine
Unit of the University of Florence, subjects who met the following
inclusion criteria were invited to take part in this prospective longi-
tudinal study: Caucasian ethnicity, no smoking, absence of hyperem-
esis that can affect adequate food consumption, singleton pregnancy,
absence of chronic hypertension, absence of chronic illness that can
affect fetal growth, pregestational body mass index (BMI) between 19
and 25 kg/m2, and absence of GDM as recommended by the Fourth
International Workshop Conference on Gestational Diabetes Mellitus
(32). We tried to elude those conditions, which are more prevalent in
individuals with a history of low birth weight, to avoid a possible
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impact of low maternal birth weight on fetal growth. Nonetheless, in
our studied women, a history of maternal low birth weight (2,500 g)
was present in 11.1% of the FGR women and in 9.1% of the control
women (P  not significant), thus having no impact on sample
heterogeneity.
All women were instructed to follow a correct meal plan with an
adequate caloric intake calculated on prepregnancy BMI; the meal
plan was adjusted during pregnancy to be suitable throughout preg-
nancy, and its adherence during pregnancy was regularly checked.
Women were also instructed to follow a moderate physical activity
(30 min of walking per day).
The study protocol, carried out according to the Helsinki Declara-
tion, was approved by the local ethics committee, and written in-
formed consent was obtained from each subject before they joined the
study protocol. A total of 1,814 women were recruited. Following a
10- to 12-h overnight fast, fasting blood samples were taken, and then
a solution containing 75 g of glucose was ingested, and venous blood
samples were drawn for glucose and insulin determination at 60 and
120 min.
Plasma glucose levels were measured using the glucose oxidase
method (19) and plasma insulin levels using a double antibody
radioimmunoassay (16). Plasma glucose values 95 mg/dl at fasting,
180 mg/dl at 60 min, and 155 mg/dl at 120 min were considered
normal (32). Insulin resistance was assessed with the homeostatic
model (HOMA), calculated as the product of fasting glucose and
insulin. However, for characterizing the metabolic state of the moth-
ers, we instead used measurements of insulin sensitivity (33). In
particular, in fasting conditions, we adopted the quantitative insulin
sensitivity check index (QUICKI)  1/[log (fasting glucose)  log
(fasting insulin)] (20), whereas, in dynamic “postprandial” conditions,
i.e., during the OGTT, we adopted the oral glucose insulin sensitivity
(OGIS) index (ml min1 m2) (30). This index, whose calculation is
available at http://webmet.pd.cnr.it/ogis/ (last check: March 15, 2011),
derives from a mathematical model of glucose kinetics after an oral
load of glucose and quantifies glucose clearance per unit change of
insulin. OGIS has thus been found to represent total glucose disposal,
i.e., whole body insulin sensitivity (1). Both indices, which have
previously been validated against the euglycemic clamp (20, 29, 30,
41), are widely used (1) also in pregnancy (26, 35). The areas under
the concentration curve (AUC) were calculated with the trapezoidal
rule. -Cell function was calculated with a modified insulinogenic
index as AUCinsulin/AUCglucose (Uinsulin/mgglucose). Both the ca-
pacity of the -cell to adapt to changes in insulin sensitivity and the
ability of insulin to dispose of glucose in relation to the prevailing
insulin concentration are described by the product OGIS 
(AUCinsulin/AUCglucose), sometimes called disposition index, and
have already been widely exploited in previous studies (e.g., Ref. 27).
All these indices provide a quantitative figure of the overall metabolic
status by simultaneously accounting for insulin action and secretion.
Fetal growth restriction was defined as a birth weight below the 5th
percentile for gestational age according to Italian birth weight distri-
bution (34) in the absence of preeclampsia, autoimmune disease, type
1 or 2 diabetes, uterine malformations, fetal congenital malformations
or chromosomal abnormalities, viral infections, or drug or alcohol
abuse during pregnancy.
Statistical analysis. Data are expressed as means 	 SD. ANOVA
or Student’s t-test for unpaired data was used for the comparison of
continuous variables between groups. When kurtosis and skewness
values indicated a nonnormal distribution, statistical difference be-
tween groups was determined according to the nonparametric Wil-
coxon-Mann-Whitney test; median values were presented.
Simple linear regression and multiple regression were used to
explore the linear relationship among the variables. The general
equation was of the form Y  a  b1  X1  b2  X2  . . .  bp 
Xp, where the regression coefficient bp indicates the independent
contributions of each independent variable to the prediction of the
dependent variable. ANOVA statistics were used to assess the signif-
icance of the regression and accepted for P  0.05.
Receiver-operating characteristic curves [ROC; a graph of sensi-
tivity vs. (1-specificity)] (17) were constructed on a logistic regression
to compare the ability of the various parameters of insulin resistance
to discriminate between the patients according to the presence or not
of FGR. Sensitivity and specificity, statistical measurements of the
performance of a diagnostic test, were calculated and reported for the
optimal cutoff value.
RESULTS
By applying the selection criteria, among the 1,814 studied
women, 99 (5.5%) have had a baby with birth weight below the
5th percentile for gestational age (FGR group). The remaining
women (n  1,715) were considered as control subjects
(CNT). The characteristics of the two groups are reported in
Table 1. At the time of the study (27th gestation wk), fasting
glucose was identical in the two groups, whereas insulin was
lower in FGR group. This fact yielded a lower fasting insulin
resistance (HOMA) and consequently a fasting insulin sensitivity
(QUICKI) that was much higher in the FGR group. FGR
women delivered earlier with respect to CNT (36.1 	 2.4 vs.
39.4	 1.3 gestational wk, P 0.0001) and had a lower weight
gain during pregnancy. The anthropometric characteristics of
the newborn are reported in Table 1. Furthermore, no sex
differences were found between the two groups (CNT group:
males 51%, females 49%; FGR group: males 50%, females
52%; P  0.3).
Glucose and insulin levels during OGTT obtained in the two
groups are reported in Table 2 along with the dynamic param-
eters. The glucose and insulin patterns were significantly lower
at any measured data point in the FGR group. These women
exhibited higher dynamic insulin sensitivity (OGIS) and -cell
function (insulinogenic index), which in turn yielded more
elevated disposition index.
The presence of a correlation between newborn weight and
glucometabolic indices (QUICKI, OGIS, and AUCinsulin/
AUCglucose) was evaluated by using multiple regression anal-
ysis (Table 3). Considering the subjects altogether, the three
metabolic indices resulted as significant contributors to the
overall variability in newborn weight (P  0.0001). Con-
versely, considering the CNT group of subjects, only OGIS
was a predictive variable (P 0.0001) for the newborn weight.
Considering the FRG group, QUICKI and OGIS appeared as
Table 1. Clinical characteristics and pregnancy outcome
of the 2 groups of women studied
FGR (n  99) CNT (n  1,715) P Value†
Age, yr 30 	 5 31	 4 0.07568
Body mass index, kg/m2 22.11 	 2.12 21.90 	 1.90 0.29000
Gestational week* 27.45	 0.92 27.31 	 0.84 0.12195
Newborn birth weight, g 1.861 	 451 3.380 	 392 0.00001
Newborn birth length, cm 45.9 	 1.8 49.2 	 1.8 0.00001
Ponderal index, g/cm3 2.6 	 0.3 2.9	 0.4 0.00001
Birth weight percentile 3.4	 0.9 56.5	 23.7 0.00001
Weight gain during
pregnancy, kg 7.1	 2.9 11.8	 3.6 0.00001
Data are expressed as means 	 SD. FGR, women with fetal growth-
restricted newborn; CNT, control women. *When the study was performed.
†Statistical assessment of differences between the 2 groups was obtained by
Student’s t-test.
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significant independent variables (P 0.0001 and P 0.0366,
respectively).
The relevance of QUICKI as regressor against newborn
weight was further individually evaluated by simple linear
regression. As shown in the scatter plot of Fig. 1, a significant
regression was obtained for FRG and also for the subjects
altogether, but no significant regression was detected for the
CNT group only, indicating that the contribution of CNT group
to the overall correlation is only marginal.
To evaluate the possible role of the metabolic indices as
predictors of newborn weight, a binary logistic regression was
fitted according to the occurrence or not of FRG. As Fig. 2
shows, the fitted curve model was significant (P  0.0001),
and consequently, a ROC curve was performed. The AUC
under the ROC curve (AUCr) was 0.68, and the specificity 82%,
with sensitivity of 46% at a cutoff QUICKI value of 0.44.
Considering the other metabolic indices, a quite lower perfor-
mance of the tests was found from ROC curve analysis (Table 4).
Regarding the clinical factors that could predict the newborn
weight, the multiple regression analysis with birth weight as
dependent variable and prepregnancy BMI, age, gestational
week of OGTT evaluation, weight gain during pregnancy, and
gestational age at delivery as independent variables yielded
that age, gestational age at delivery, and weight gain were
predictors (respective multiple regression coefficients were
7.45, 108.92, and 85.12, all P  0.0001), whereas no signifi-
cant relation was found for BMI (0.37, P  0.93) nor for
gestational week of OGTT evaluation (13.94, P  0.12).
DISCUSSION
The results of our study show that women with FGR babies
had increased insulin sensitivity with respect to control moth-
ers. Insulin sensitivity evaluation with QUICKI at fasting and
with OGIS in dynamic conditions suggests that both parame-
ters are related to fetal growth. Previous studies have analyzed
FGR mothers but almost exclusively in a restricted group of
subjects. Here, we were able to study a very large group of
well-characterized subjects and, therefore, to segregate a quite
high number of mothers who gave birth to small babies. It is
worth noting that we selected pregnant women with normal
body weight to avoid any modification of insulin sensitivity
related to overweight and or obesity (14).
Pregnancy is characterized by changes in women’s hor-
monal status and metabolism (13, 24). The ability to regulate
nutrient balance during this period is critical to the health of the
mother and of the growing fetus. An important metabolic
change is a decrease in insulin sensitivity that helps to optimize
metabolic efficiency playing an important role in regulation of
maternal fat accretion and fetal growth. Several authors have
shown that, in physiological pregnancy, mothers’ anthropo-
metric characteristics and carbohydrate metabolism are the
most important determinants of fetal growth (2, 7). It is well
known that an increase of maternal insulin resistance, as
happens for example in gestational diabetic patients and/or in
obese women, can cause an excessive fetal growth (6, 14, 36,
38). However, much less information is available on the
interaction between maternal metabolism and FGR. Some
Table 2. OGTT values and derived fasting and dynamic metabolic parameters
FGR (n  99) CNT (n  1,715) P Value†
Fasting glucose, mg/dl 75.3	 8.4 (74) 75.4	 7.5 (75) 0.5296
Glucose, mg/dl
At 60 min 98.1 	 16.1 (99) 116.2	 17.8 (123) 0.0001
At 120 min 91.1 	 16.1 (90) 103.9	 18.2 (105) 0.0001
Fasting insulin, U/ml 4.20	 3.90 (2.89) 6.67	 6.58 (5.23) 0.0001
Insulin, U/ml
At 60 min 54.67 	 34.51 (44.60) 61.87	 33.03 (55.40) 0.0044
At 120 min 40.22 	 24.64 (35.90) 52.14	 36.93 (43.40) 0.0003
HOMA-IR 0.77	 0.75 (0.57) 1.23	 1.32 (0.93) 0.0001
QUICKI 0.460	 0.133 (0.420) 0.396	 0.061 (0.387) 0.0001
AUCinsulin, U/l in 2 h 4.6 	 2.6 (3.8) 5.5	 2.9 (4.9) 0.0009
OGIS, ml  min1  m2 466.4 	 69.9 (466.9) 444.4	 65.3 (440.5) 0.0022
Insulinogenic index, U/mg 222	 196 (154) 160	 110 (134) 0.0192
Disposition index 981	 802 (719) 700	 512 (583) 0.0006
Data are expressed as means	 SD (median in parentheses). OGTT, oral glucose tolerance test; HOMA-IR, homeostatis model assessment of insulin resistance;
QUICKI, quantitative insulin sensitivity check index; AUC, area under the concentration curve; OGIS, oral glucose insulin sensitivity. †Statistical difference
between the 2 groups was determined according to Wilcoxon-Mann-Whitney nonparametric test.
Table 3. Parameters obtained with multiple regression analysis of the data assuming the weight of newborn as dependent
variable and the glucose metabolic indices as independent (explanatory) variables
Groups of Subjects a (Intercept)
Independent Variables
QUICKI OGIS Insulinogenic index
All subjects (n  1814) 4,250.913 b1  1,220.863, P  0.0001 b2  0.8631, P  0.0001 b3  43.2098, P  0.0001
CNT (n  1715) 3,661.338 b1  90.5437, P  0.5835 b2  0.6845, P  0.0001 b3  7.3312, P  0.4054
FGR (n  99) 3,233.129 b1  1,456.155, P  0.0001 b2  1.5163, P  0.0366 b3  0.4072, P  0.9869
Multiple regression was fitted to the following model: [newborn weight]  a  b1  QUICKI  b2  OGIS  b3  AUCi/AUCg. a is the intercept with the
y-axis; b1, b2 and b3 are the respective regression coefficients of the 3 independent variables.
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authors have reported a link between reduced birth weight and
low glucose and insulin levels after glucose load (22, 25, 37,
39). Caruso et al. (11) have shown, with the hyperinsulinemic
euglycemic clamp, an increase in insulin sensitivity in eight
mothers with unexplained FGR newborns. Our study, simply
utilizing the data obtained from an OGTT, confirms in a large
number of patients the conclusions of Caruso et al. (11) and
demonstrates that some indices of insulin sensitivity are pre-
dictive of unexplained FGR.
The normal response in pregnancy of decreased maternal
insulin sensitivity to allow the passage of glucose to the
developing fetus would seem to be reduced or absent in the
mothers of FGR fetuses. When, for whatever reasons, this
maternal adaptation that is essential for fetal growth is com-
promised, the result could be undernourished fetuses. So we
can speculate that women with pregnancy complicated by FGR
failed to develop the “diabetogenic state” of pregnancy; the
lack of increasing insulin resistance can induce a reduction of
nutrients’ availability to the fetus, resulting in FGR.
The AUCr is related to the ability of the test to discriminate
between subjects. An AUCr of 1 describes a perfect test, with
a sensitivity of 100% and specificity of 100%; in general,
AUCr of 0.5–0.7 is associated with marginally useful tests,
AUCr of 0.7–0.9 is associated with a good test, and AUCr

0.9 is associated with an excellent test. Since the AUCr
obtained with the considered parameters was in the range of
0.58 to 0.68, we cannot recommend them as the only variables
to be directly screened for the prediction of growth-restricted
newborns. However, although caution must be used in inter-
preting data emanating from them, they clearly represent in-
teresting and informative parameters to be monitored in preg-
nancy. Moreover, the present data suggest an acceptable level
of performance; since when a test becomes more sensitive it
becomes less specific and vice versa, we just looked for the
cutoff values, allowing the best combination of sensitivity and
specificity. The test appeared to display a very good specificity
(that is, the probability of a negative test among subjects
Fig. 1. Correlation between birth weight and quantitative insulin sensitivity
check index (QUICKI) for all subjects (n  1,814). Linear regression: birth
weight  3,869  1,431  QUICKI; Pearson’s correlation coefficient r 
0.187, P  0.0001. For fetal growth restriction (FGR) only (n  99; red
points), linear regression: birth weight  2,592  1,589  QUICKI; r 
0.470, P  0.0001. For control (n  1,715; blue points), linear regression
was not statistically significant: birth weight  3,402  58  QUICKI, r 
0.009, P 0.707. Ovals indicate the respective 95% confidence areas for the
2 groups of subjects.
Fig. 2. Logistic regression (top) and consequent receiver-operated character-
istic (ROC) curve (bottom) for the parameter QUICKI to discriminate between
the patients according to FGR. Area under ROC curve was 0.68; sensitivity
was 46% and specificity 82% at the cutoff QUICKI value of 0.44. See also
Table 4 for other metabolic parameters considered.
Table 4. Parameters obtained from ROC curve after
nominal logistic regression on different metabolic




Curve Cutoff Value Sensitivity, % Specificity, %
QUICKI 0.68 0.44 46 82
OGIS 0.59 497 39 81
Insulinogenic index 0.58 2.02 41 79
Disposition index 0.61 631.5 65 58
ROC, receiver-operated characteristics.
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without the pathology, i.e., true negative), but to the detriment
of sensitivity (the probability of a positive test among subjects
presenting the pathological characteristic under study, i.e., true
positive). From the above results it seems that QUICKI, which
reflects changes mainly in hepatic insulin sensitivity, is a better
predictor of FGR with respect to OGIS, which correlates better
with total (mostly peripheral) glucose disposal. Endogenous
hepatic glucose production was shown to remain sensitive to
increased insulin concentration in normal pregnancy (96%
suppression) but less sensitive in GDM (80% suppression) (5).
Increased insulin sensitivity in the women in our study sug-
gests that the suppression of endogenous hepatic glucose pro-
duction may increase with less availability of glucose to
dispose of. Moreover, our results suggest that the chronic
resistance state, such as that reflected by the fasting measure-
ments, plays a more superior role than the acute one reflected
by the dynamic OGTT. Thus, simple fasting indices of insulin
action, such as QUICKI, could provide a noninvasive way for
wide-scale screening for insulin sensitivity and risk of FGR.
Methods of proven efficacy for prevention of FGR are not
available; however, some evidence suggests that perinatal
outcome can be improved by a strict obstetrical management
and optimization of the timing of delivery. Since the glucose
tolerance test is already widely used for gestational diabetes
screening, the simple addition of a fasting insulinemia assay,
using the same blood drawing for plasma glucose, would
enable a further possibility for improving the care to pregnant
women so to reduce the neonatal morbidity and mortality. The
possible impact of dietary advice and the type of dietary advice
in the behavior of fetal growth in these women remain to be
established.
As for the relationship between weight gain during preg-
nancy, gestational age at delivery, and fetal growth, we found
that these data can be related to the fact that women with FGR
babies delivered earlier than control ones, even in absence of
maternal and/or placental disease. Some studies have shown a
strong correlation between low weekly maternal weight gain
during pregnancy (0.2 kg/wk) and fetal undergrowth (40). In
our study, the weight gain during pregnancy was never below
0.2 kg/wk. As for delivery, there are no clear recommendations
for the best mode and timing in the presence of FGR babies;
however, it has been demonstrated that perinatal mortality and
morbidity is markedly increased in FGR fetuses (12, 28).
Therefore, time of delivery is crucial to avoid fetal complica-
tions, and this justifies the prudent approach of the gynecolo-
gists involved in this study to deliver the growth-restricted
infants before term, as soon as fetal lung maturity has been
achieved (28).
A limitation of this study is the lack of blood analysis of
hormones, such as TNF, human placental lactogen, human
placental growth hormone, and adiponectin, known to be
related to the development of insulin resistance during preg-
nancy (31). The strength is nonetheless that, to the best of our
knowledge, this is the largest sample of normal-weight, nor-
motensive pregnant women with normal glucose tolerance
studied so far with respect to carbohydrate metabolism and
unexplained FGR.
In conclusion, elevated insulin sensitivity seems to be one of
the factors involved in determining unexplained fetal growth
retardation; its assessment, even only in the fasting state, could
be useful to guide any possible monitoring and therapeutic
strategies to reduce fetal complications.
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